Profile Name | FBXW7 R465H |
Gene Variant Detail | |
Relevant Treatment Approaches | mTORC1 Inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | FBXW7 R465H | lung adenocarcinoma | sensitive | mTORC1 Inhibitor | Temsirolimus | Clinical Study | Actionable | In a clinical case report, a patient with lung adenocarcinoma harboring FBXW7 R465H demonstrated tumor shrinkage when treated with Torisel (temsirolimus) (PMID: 24360397). | 24360397 | FBXW7 R465H | T-cell adult acute lymphocytic leukemia | resistant | MRK-003 | Preclinical | Actionable | In a preclinical study, FBXW7 R465H conferred resistance to gamma secretase inhibitor, MRK-003, by activation of the NOTCH pathway and stablization of MYC as demonstrated in T cell acute lymphoblastic leukemia (T-ALL) cell lines (PMID: 17646409). | 17646409 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|